LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric diseases, including schizophrenia and bipolar depression. Its lead candidate, LB-102, is an oral small-molecule benzamide antipsychotic designed as a new chemical entity related to amisulpride, with late-stage studies in acute schizophrenia and other mood indications. The company is pre-commercial, with value tied to clinical progress rather than product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -5.3 | — |
| Q2 2025 | 0 | — | -4.9 | — |
| Q3 2025 | 0 | — | -3.6 | — |
| Q4 2025 | 0 | — | -11.5 | — |
| Q1 2026 | 0 | — | -19.1 | — |
| Q2 2026 | 0 | — | -51.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: WEBTOON Entertainment Inc. (WBTN), Cronos Group Inc. (CRON), Taysha Gene Therapies, Inc. (TSHA), Jefferson Capital, Inc. (JCAP), Omeros Corporation (OMER), Harmonic Inc. (HLIT)